Stocks in play: ProMIS Neurosciences, Inc.

And BC Neuroimmunology Lab (BCNI), have entered into a revenue-sharing joint venture (JV) agreement to develop and offer highly accurate and objective tests for detection, diagnosis and monitoring of Alzheimer’s disease (AD). Significant progress has been made over the past several years to advance a more precise diagnosis of AD. In particular, introduction of the A/T/N (amyloid/tau/neurodegeneration) criteria two years ago offered an unbiased approach for the objective biological diagnosis of AD1. However, the A/T/N diagnostic approach, until recently, required either costly PET and MRI scan assessments or an invasive lumbar puncture to secure cerebrospinal fluid to measure specific biomarkers. ProMIS Neurosciences, Inc shares T.PMN are trading up $0.005 at $0.22.

Read:

• Gold Prices Just Hit a Nine-Year High, and Could Test $1,900 Shortly

• The Top 5 Plant-Based Product Companies Sprouting in 2020

• Like Tesla, Nikola and the Entire EV Space? This Stock is KULR

• Electric Vehicle "Second Life" Batteries are Fueling a Sizable Microgrid Boom